ArticleAlzheimer's research & therapy2018

FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer's disease.

Petr Novak et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.